Form 4: Mineralys Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Lonnel Coats, a Director of Mineralys Therapeutics, Inc., reported multiple transactions in common stock on October 19, 2026.
Summary
- Grant/award: acquired 12,400 Common Stock on October 19, 2026; holds 12,400 after (Direct).
- Grant/award: acquired 16,600 Stock Option on October 19, 2026; holds 16,600 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Lonnel Coats — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-19 | Grant/award | Common Stock | 12,400 | — | — | 12,400 |
| 2026-10-19 | Grant/award | Stock Option | 16,600 | — | — | 16,600 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-19 | Grant/award (12,400 shares) |
| 2026-10-19 | Grant/award (16,600 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., neutral, Lonnel Coats
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.